Correcting anemia and native vitamin D supplementation in kidney transplant recipients: a multicenter, 2 × 2 factorial, open-label, randomized clinical trial.

What Was Tested

This randomized controlled trial looks at Vitamin D, K2, Magnesium and Zinc in the context of anemia.

The researchers conducted a multicenter, two-by-two factorial, open-label, randomized clinical trial to examine the effects of anemia correction and vitamin D supplementation on 2-year change in eGFR among KTRs (CANDLE-KIT).

Why It Was Studied

This trial was terminated early based on the planned interim intention-to-treat analyses (α = 0.034).

Who Took Part

According to the abstract, 153 patients were involved.

How the Study Was Run

In design terms this was a randomized, open-label and multicenter study.

The patients were allocated by chance, so the Vitamin D, K2, Magnesium and Zinc group and the comparison group should start out alike.

Everyone knew when Vitamin D, K2, Magnesium and Zinc was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.

Running at several centres spread the Vitamin D, K2, Magnesium and Zinc study over different clinics and patient groups.

What Was Measured

The subject headings attached to it are Anemia, Dietary Supplements, Japan, Kidney Transplantation and Vitamin D.

The authors tagged it with the keywords allograft function, cancer, erythropoiesis-stimulating agents and malignancy.

What This Means in Plain Language

The paper is a randomized, open-label and multicenter study of Vitamin D, K2, Magnesium and Zinc in 153 patients in people with anemia.

The publication is from 2021 (Transplant international : official journal of the European Society for Organ Transplantation), a journal based in Switzerland.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, Anemia research.